CBD Pretreatment Reduced THC-Induced Paranoia and Memory Impairment in Healthy Volunteers
Pre-treatment with 600 mg oral CBD significantly reduced THC-induced paranoia and prevented the memory impairment normally caused by intravenous THC in healthy volunteers.
Quick Facts
What This Study Found
In a between-subjects, double-blind design, 48 healthy participants received either 600 mg oral CBD (n=22) or placebo (n=26) before intravenous THC (1.5 mg). CBD pretreatment produced two key protective effects.
First, clinically significant psychotic symptoms (3+ point increase on PANSS positive scale) were significantly less likely in the CBD group (OR=0.22), and paranoia scores were significantly lower. Second, verbal learning memory (HVLT-R) declined by 10.6% in the placebo group but only 0.4% in the CBD group, essentially eliminating THC's memory-impairing effect.
Key Numbers
48 participants. CBD 600 mg oral, 210 min before THC 1.5 mg IV. Clinically significant psychosis: OR=0.22 in CBD group (p<0.05). Paranoia: significantly lower in CBD group (p<0.05). Memory decline: -10.6% (placebo) vs. -0.4% (CBD) (p<0.05).
How They Did This
Between-subjects, double-blind, placebo-controlled RCT. 48 healthy participants (22 CBD, 26 placebo). CBD 600 mg oral administered 210 minutes before IV THC 1.5 mg. Outcomes: PANSS positive scores, State Social Paranoia Scale, Hopkins Verbal Learning Task-Revised.
Why This Research Matters
This study provides experimental evidence for the epidemiological observation that high-THC/low-CBD cannabis products are more harmful than balanced-ratio products. It also suggests CBD could serve as a protective agent against THC's negative psychiatric effects, with implications for medical cannabis formulation.
The Bigger Picture
This is one of the most important experimental studies demonstrating that CBD can protect against specific harms of THC. It provides a pharmacological basis for cannabis regulation: products with higher CBD-to-THC ratios may be inherently safer for mental health.
What This Study Doesn't Tell Us
The between-subjects design means individual differences may have contributed. A single high IV THC dose is not equivalent to chronic cannabis smoking. The oral CBD was given 3.5 hours before IV THC, which may not reflect typical cannabis use where both cannabinoids are consumed simultaneously. The sample was healthy volunteers without psychosis risk factors.
Questions This Raises
- ?Would CBD protect against THC effects in people with psychosis vulnerability?
- ?What CBD-to-THC ratio provides optimal protection?
- ?Should cannabis regulations mandate minimum CBD content?
- ?Does smoked or vaped CBD provide the same protection?
Trust & Context
- Key Stat:
- CBD reduced clinically significant psychotic symptoms from THC by 78% (OR=0.22)
- Evidence Grade:
- Double-blind, placebo-controlled RCT with clear outcomes; strong evidence for CBD protection against acute THC effects.
- Study Age:
- Published in 2013. This study influenced the growing interest in CBD-to-THC ratios in cannabis products and regulation.
- Original Title:
- Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.
- Published In:
- Journal of psychopharmacology (Oxford, England), 27(1), 19-27 (2013)
- Authors:
- Englund, Amir(6), Morrison, Paul D(5), Nottage, Judith, Hague, Dominic, Kane, Fergus, Bonaccorso, Stefania, Stone, James M, Reichenberg, Avi, Brenneisen, Rudolf, Holt, David, Feilding, Amanda, Walker, Lucy, Murray, Robin M, Kapur, Shitij
- Database ID:
- RTHC-00674
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Does CBD protect against THC-induced paranoia?
In this controlled experiment, yes. Participants who received 600 mg CBD before THC were 78% less likely to experience clinically significant psychotic symptoms and had significantly less paranoia than those who received placebo before THC.
Does CBD prevent cannabis memory problems?
In this study, CBD pretreatment essentially eliminated THC's negative effect on verbal learning. The placebo group showed a 10.6% decline in memory performance after THC, while the CBD group showed only a 0.4% decline. This suggests CBD preserves hippocampal-dependent memory function that THC normally impairs.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00674APA
Englund, Amir; Morrison, Paul D; Nottage, Judith; Hague, Dominic; Kane, Fergus; Bonaccorso, Stefania; Stone, James M; Reichenberg, Avi; Brenneisen, Rudolf; Holt, David; Feilding, Amanda; Walker, Lucy; Murray, Robin M; Kapur, Shitij. (2013). Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.. Journal of psychopharmacology (Oxford, England), 27(1), 19-27. https://doi.org/10.1177/0269881112460109
MLA
Englund, Amir, et al. "Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.." Journal of psychopharmacology (Oxford, 2013. https://doi.org/10.1177/0269881112460109
RethinkTHC
RethinkTHC Research Database. "Cannabidiol inhibits THC-elicited paranoid symptoms and hipp..." RTHC-00674. Retrieved from https://rethinkthc.com/research/englund-2013-cannabidiol-inhibits-thcelicited-paranoid
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.